A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
Inthis study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with gemcitabine to patients with solid tumours.
Tumors
DRUG: MGCD0103|DRUG: Gemcitabine
Maximum tolerated dose in combination with azacitidine, 1 year (anticipated)|Response rate, 1 year (anticipated)
Objective response., 1 year (anticipated)|Pharmacodynamics (histone acetylation, biomarkers), 1 year (anticipated)
Inthis study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with gemcitabine to patients with solid tumours.